p53 and the proteasome regulate androgen receptor activity

Cancer Biology and Therapy

Volumn 13, Issue 7, 2012, Pages 553-558

  Guseva, Natalya V ^a   Rokhlin, Oskar W ^a   Glover, Rebecca A ^a   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Androgen receptor; p53; Prostate cancer; Proteasome

Indexed keywords

ANDROGEN RECEPTOR; LACTACYSTIN; PROTEASOME; PROTEIN P53;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861134158     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19605     Document Type: Article

References (21)

1. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010; 80:724-30; PMID:20450892; http://dx.doi.org/10.1016/j. bcp.2010.04.031.
2. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005; 24:6773-84; PMID:16007156; http://dx.doi.org/10.1038/sj.onc.1208833.
3. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, et al. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 2002; 21:153-7; PMID:11791186; http://dx.doi.org/10.1038/sj. onc.1205001.
4. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB. p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 2000; 19:1959-68; PMID:10773886; http://dx.doi.org/10.1038/sj.onc.1203453.
5. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9:1152-9; PMID:18084622; http://dx.doi.org/10.1593/neo.07769.
6. Wang B, Xiao Z, Ren EC. Redefining the p53 response element. Proc Natl Acad Sci USA 2009; 106:14373-8; PMID:19597154; http://dx.doi.org/10.1073/pnas. 0903284106.
7. Gudkov AV, Komarova EA. Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 2005; 331:726-36; PMID:15865929; http://dx.doi.org/10.1016/j.bbrc.2005.03.153.
8. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2:474-9; PMID:16862141; http://dx.doi.org/10.1038/nchembio809.
9. Kang Z, Pirskanen A, Jänne OA, Palvimo JJ. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 2002; 277:48366-71; PMID:12376534; http://dx.doi.org/10.1074/jbc. M209074200.
10. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002; 277:36570-6; PMID:12119296; http://dx.doi.org/10.1074/jbc.M204751200.
11. Hilser VJ, Thompson EB. Structural dynamics, intrinsic disorder and allostery in nuclear receptors as transcription factors. J Biol Chem 2011; 286:39675-82; PMID:21937423; http://dx.doi.org/10.1074/jbc.R111.278929.
12. Ping Dou Q. Proteasome inhibition and cancer therapy. Nat Rev Cancer 2011; 11:848-9.
13. Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 2006; 4:113-23; PMID:16513842; http://dx.doi.org/10.1158/1541-7786.MCR-05-0085.
14. Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate 2007; 67:1801-15; PMID:17935158; http://dx.doi.org/10. 1002/pros.20662.
15. Guseva NV, Rokhlin OV, Glover RA, Cohen MB. TOFA (5-tetradecyl-oxy-2- furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther 2011; 12:80-5; PMID:21525791; http://dx.doi.org/10. 4161/cbt.12.1.15721.
16. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 2001; 48:225-30; PMID:11536301; http://dx.doi.org/10.1002/pros.1101.
17. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998; 83:2534-9; PMID:9874460; http://dx.doi.org/10.1002/ (SICI)1097-0142(19981215)83:12〈2534::AIDCNCR19〉3.0.CO;2-V.
18. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995; 1:1111-8; PMID:9815901.
19. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9:1152-9; PMID:18084622; http://dx.doi.org/10.1593/neo.07769.
20. Anaganti S, Fernández-Cuesta L, Langerød A, Hainaut P, Olivier M. p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Lett 2011; 300:215-24; PMID:21071137; http://dx.doi.org/10.1016/j.canlet.2010.10.008.
21. Golubovskaya VM, Zheng M, Zhang L, Li JL, Cance WG. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009; 9:280; PMID:19671193; http://dx.doi.org/10.1186/1471-2407-9-280.